Clik here to view.
Chi-Med Announces the Full Exercise of Underwriters’ Over-allotment Option
LONDON NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION...
View ArticleClik here to view.
Otsuka to Host Web Briefing on Tolvaptan Phase 3 Trial Results in Polycystic...
TOKYO & PRINCETON, N.J. Otsuka Pharmaceutical Co., Ltd. (OPCJ) and its affiliate Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) are pleased to invite investors and media...
View ArticleClik here to view.
Astellas Reports First Half FY2017 Financial Results, Revises Fiscal Year...
TOKYO Astellas Pharma Inc. (TOKYO:4503) (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced the financial results for the first six months of fiscal year 2017, ending March 31, 2018...
View ArticleClik here to view.
Big Investment in Aroa Biosurgery’s Commercial Partner
AUCKLAND, New Zealand New Zealand biomedical company Aroa Biosurgery faces accelerating growth after a significant investment of up to US$25 million in its surgical partner for commercial expansion....
View ArticleClik here to view.
International Conference Addresses Clinical Applications and New Innovations...
ST. PAUL, Minn. The future is bright for lingual orthodontic treatment and the Incognito™ System, as demonstrated at the 2017 Incognito Appliance System International User Meeting, held in October...
View ArticleClik here to view.
Sterigenics International LLC Acquires Toxikon’s European Laboratory Business
CLEVELAND Sterigenics International LLC announced today that it has acquired Toxikon Europe N.V., the European division of Toxikon Corporation, a Bedford, Mass.-based preclinical contract research...
View ArticleClik here to view.
Otsuka and Lundbeck Will Initiate a Third Phase 3 Trial to Evaluate...
TOKYO & VALBY, Denmark Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announce that the two companies will initiate a third clinical phase 3 study for brexpiprazole in...
View ArticleClik here to view.
Takeda to Showcase Data That May Reshape the Future of Blood Cancer...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it will present a total of 11 company-sponsored abstracts at the 59th American Society of...
View ArticleClik here to view.
3M™のインコグニトアプライアンスシステムに関する臨床応用と新たな革新成果が国際会議で取り上げられる
米ミネソタ州セントポール （ビジネスワイヤ） — 10月にフランスのパリで開催された2017年インコグニトアプライアンスシステム国際ユーザー会議で示されたように、舌側矯正とインコグニトシステム（Incognito™ System）の将来は明るいものとなっています。 本プレスリリースではマルチメディアを使用しています。リリースの全文はこちらをご覧ください。：...
View ArticleClik here to view.
Cerveau Technologies and Sinotau Pharmaceutical Group Announce Sinotau’s...
BOSTON Sinotau Pharmaceuticals has announced today an agreement with HTA CO. LTD for launching a new β-amyloid imaging agent for Alzheimer’s disease in China. “This agreement will greatly contribute...
View ArticleClik here to view.
Health Canada Approves Otsuka and Lundbeck’s Abilify Maintena® (Aripiprazole...
MONTREAL Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada announce that Health Canada issued a Notice of Compliance for ABILIFY MAINTENA (aripiprazole for prolonged release injectable...
View ArticleClik here to view.
Altemia™治疗镰状细胞病(SCD)患儿获得临床成功
佛罗里达州里维埃拉海滩 — (美国商业资讯) — Sancilio Pharmaceuticals Company, Inc. (SPCI)今天宣布，一项评估Altemia™口服软明胶胶囊治疗5-17岁镰状细胞病患儿有效性和安全性的临床研究获得阳性先期结果 (https://clinicaltrials.gov/ct2/show/NCT02973360)。...
View ArticleClik here to view.
Otsuka Announces Phase 3 Results for Tolvaptan in Patients with Autosomal...
TOKYO Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced detailed results from the Phase 3 REPRISE trial of tolvaptan, which is under investigation in the United States in patients with...
View ArticleClik here to view.
Otsuka Announces Phase 3 Results for Tolvaptan in Patients with Autosomal...
TOKYO Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced detailed results from the Phase 3 REPRISE trial of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD)....
View ArticleClik here to view.
Alexion Receives New Japanese Patent for Soliris® (eculizumab), Extending...
NEW HAVEN, Conn. Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that the Japanese Patent Office (JPO) has issued patent No. 6224059, directed to the composition of matter of eculizumab...
View ArticleClik here to view.
武田在美国血液学会第59届年会上呈报的数据有望重塑血液肿瘤治疗的未来
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:...
View ArticleClik here to view.
Takeda’s Dengue Vaccine Candidate Associated with Reduced Incidence of Dengue...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502), (“Takeda”) today announced that data from an 18-month interim analysis of the ongoing Phase 2 DEN-204 trial of its live, attenuated...
View ArticleClik here to view.
アヴェオ・オンコロジーとEUSA Pharma、腎細胞がんでチボザニブとニボルマブを検討する第1/2相TiNivo試験の第1相部分の有望な結果を発表
米マサチューセッツ州ケンブリッジ & 英ヘメルヘムステッド （ビジネスワイヤ） — アヴェオ・オンコロジー（NASDAQ:AVEO）とEUSA Pharmaは本日、TiNivo試験の進行中の第1相部分から得た有望な結果を報告したと発表しました。TiNivo試験は、進行性腎細胞がん（RCC）の治療を目的として、ブリストル・マイヤーズ...
View ArticleClik here to view.
Takeda and Portal Instruments Announce Collaboration to Develop Needle-Free...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda Pharmaceutical Company Limited (TSE: 4502) and Portal Instruments today announced a collaboration to develop and commercialize Portal’s needle-free drug...
View ArticleClik here to view.
EOC Pharma Completed Series B Financing From Leading Global Investors
SHANGHAI EOC Pharma Group (EOC), a leading oncology-focused development and commercialization company in China, today announced that it has completed a $32 million Series B financing led by Taikang...
View Article